Receive The Newest Study Notifications

Zai Lab and Novocure Announce First Patient Enrolled in a Phase 2 Pilot Trial of Tumor Treating Fields Together with Chemotherapy as First-Line Treatment of Gastric Cancer

by Lance Smith | Jan 10, 2020 | Study Scavenger Clinical Trial Recruitment Platform

SHANGHAI & ST. HELIER, Jersey–(BUSINESS WIRE)–Zai Lab Limited (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, and Novocure (NASDAQ: NVCR), a global oncology company with a proprietary platform technology...

Evelo Provides Update on Recent Positive EDP1815 Regulatory Interactions on Phase 2 Trial Design Resulting in Shorter Development Timeline to Registration

by Lance Smith | Jan 10, 2020 | Study Scavenger Clinical Trial Recruitment Platform

— EDP1815 Phase 2 Interim Data in Psoriasis Expected by Year-End 2020 — CAMBRIDGE, Mass., Jan. 10, 2020 (GLOBE NEWSWIRE) — Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered,...

Moderna Announces Additional Positive Phase 1 Data from Cytomegalovirus (CMV) Vaccine (mRNA-1647) and First Participant Dosed in Phase 2 Study

by Lance Smith | Jan 10, 2020 | Study Scavenger Clinical Trial Recruitment Platform

New interim analysis after third and final vaccination shows continued boosting of neutralizing antibody titers in both seronegative participants (exceeding seropositive baseline levels 10-fold at 90 and 180 µg) and seropositive participants (exceeding baseline levels...

Phase I clinical trial results published for Invectys DNA Vaccine for Cancer using PharmaJet Needle-free injector

by Lance Smith | Jan 9, 2020 | Study Scavenger Clinical Trial Recruitment Platform

GOLDEN, Colo., Jan. 8, 2020 /PRNewswire/ — PharmaJet, the maker of innovative, needle-free injection technology, announced that the results of the Invectys Phase I clinical trial of its therapeutic cancer vaccine, INVAC-1, using the PharmaJet needle-free...

TLC Announces Dosing of First Patients in Part 2 of TLC590 Phase II Trial for Postsurgical Pain following Bunionectomy

by Lance Smith | Jan 9, 2020 | Study Scavenger Clinical Trial Recruitment Platform

Part 2 will dose ~150 patients with TLC590, bupivacaine, or placebo Primary endpoint: AUC0-72 on numerical pain rating scale Enrollment of all patients to take ~3 months SOUTH SAN FRANCISCO, CA and TAIPEI, Taiwan , Jan. 08, 2020 (GLOBE NEWSWIRE) — TLC ( TLC,...

PellePharm Initiates Phase 2 Clinical Trial of Patidegib Topical Gel for People With High Frequency Basal Cell Carcinoma

by Lance Smith | Jan 9, 2020 | Study Scavenger Clinical Trial Recruitment Platform

PellePharm, Inc., a BridgeBio Pharma, Inc. (Nasdaq: BBIO) company, today announced it has dosed the first two participants in a Phase 2 clinical trial of Patidegib Topical Gel, 2%, vs. vehicle gel for people with non-Gorlin High Frequency Basal Cell Carcinoma...